Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia

American Journal of Hematology

Volumn 71, Issue 1, 2002, Pages 1-6

  Ruggeri, Marco ^a   Gisslinger, Heinz ^b   Tosetto, Alberto ^a   Rintelen, Claudia ^b   Mannhalter, Christine ^b   Pabinger, Ingrid ^b   Heis, Navide ^b   Castaman, Giancarlo ^a   Missiaglia, Edoardo ^a   Lechner, Klaus ^b   Rodeghiero, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Essential thrombocythemia; Factor V Leiden; Polycythemia vera; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BUSULFAN; HYDROXYUREA; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PHLEBOTOMY; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; THROMBOCYTHEMIA; THROMBOEMBOLISM; THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ANTICOAGULANTS; AUSTRIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PREVALENCE; RECURRENCE; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPHILIA; VENOUS THROMBOSIS; WARFARIN;

EID: 0036735354     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10153     Document Type: Article

References (33)

1. Bleeding and thrombosis in the myeloproliferative disorders
2. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
3. Therapeutic recommendation in polycythemia vera based on Polycythemia Vera Study Group protocols
4. Hydroxyurea in the treatment of patients with essential thrombocytemia at high risk of thrombosis: A prospective randomized trial
5. Low protein S in essential thrombocythemia with thrombosis
6. Decreased free protein S levels in polycyhemia vera
7. Acquired coagulation defects in myeloproliferative disorders
8. The fibrinolytic system and protein C and S in treated polycythaemia rubra vera
9. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis
10. Reduction of antithrombin III, Protein C and Protein S levels and activated Protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis
11. Homocysteine levels in polycythaemia vera and essential thrombocythemia
12. Mutation in blood coagulation factor V associated with resistance to activated protein C
13. No treatment for low-risk thrombocythemia: Results from a prospective study
14. Mortality ad causes of death in families with the factor V Leiden mutation (resistance to activated protein C)
15. Randomised trial of prophylactic daily aspirin in British male doctors
16. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population
17. Deep vein thrombosis
18. Phenotypic resistance to activated Protein C and FV Leiden mutation in the general population
19. Gruppo Italiano Studio Policitemia Vera: Polycythemia Vera, the natural history of 1213 patients followed for 20 years
20. Essential thrombocythemia: Preliminary data of a retrospective study concerning two thousand patients
21. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism
22. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis
23. Clinical significance of the FV:Q506 mutation in unselected oncology patients
24. The factor V Leiden mutation in children wirh cancer and thrombosis
25. The prevalence of poor anticoagulant response to activated protein C (APC-resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects
26. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A)
27. Mutation in the gene coding for coagulation factor V and the risk of miocardial infarction, stroke, and venous thrombosis in apparently healthy men
28. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
29. Major vascular complications in essential thrombocythemia: A study of the predictive factors in a series of 148 patients
30. Thrombotic and hemorrhagic complications in essential thrombocythemia
31. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden)
32. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
33. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: Rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial